Company profile for Zynerba Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patie...
At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
80 W. Lancaster Avenue Suite 300 Devon, PA 19333
Telephone
Telephone
484.581.7505
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/harmonys-pivotal-fragile-x-trial-flops-high-placebo-response-creates-discord

FIERCE BIOTECH
24 Sep 2025

https://www.prnewswire.com/news-releases/harmony-biosciences-completes-acquisition-of-zynerba-pharmaceuticals-and-expands-pipeline-301953012.html

PR NEWSWIRE
11 Oct 2023

https://www.globenewswire.com//news-release/2023/10/04/2754937/36775/en/Important-Information-for-Zynerba-Pharmaceuticals-Stockholders-to-Tender-Shares-for-the-Harmony-Transaction-Process-and-Instructions.html

GLOBENEWSWIRE
04 Oct 2023

https://www.globenewswire.com//news-release/2023/09/29/2752003/36775/en/Zynerba-Pharmaceuticals-Stockholders-Reminded-to-Tender-Shares-Before-5-00-PM-New-York-City-Time-on-Tuesday-October-10-2023.html

GLOBENEWSWIRE
29 Sep 2023

https://www.prnewswire.com/news-releases/harmony-biosciences-announces-extension-of-tender-offer-to-acquire-zynerba-pharmaceuticals-inc-301939785.html

PR NEWSWIRE
27 Sep 2023

https://www.globenewswire.com//news-release/2023/09/14/2743667/36775/en/Zynerba-Pharmaceuticals-Presents-Positive-Data-from-Phase-2-INSPIRE-Trial-in-22q11-2-Deletion-Syndrome-at-The-Society-for-the-Study-of-Behavioural-Phenotypes-SSBP-25th-Internationa.html

GLOBENEWSWIRE
14 Sep 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty